derived from a chronic feeding study or a long-term field study with wildlife, a Final Residue Value (FRV) for DEHP cannot be calculated and, therefore, criteria based on a FRV cannot be derived at this time.

Dated: September 13, 1995.

Tudor T. Davies,

Director, Office of Science and Technology.

References

- 1. U.S. EPA; "Quality Criteria for Water-1976"; EPA-440/9-76 023; NTIS # PB 263-943. National Technical Information Service. Springfield, VA. pp.191-192.
- 2. Federal Register notice November 28, 1980; 45 FR 79339.
- 3. U.S. EPA; "Ambient Water Quality Criteria for Phthalate Esters" October 1980, EPA-440/5-80-067.
- 4. U.S. EPA Draft "Ambient Water Quality Criteria for Di-2-Ethylhexy1 Phthalate"; September 24, 1987; 440/5–87–013.
- 5. Stephen, C.E., D.I. Mount, D.J. Hansen, J.H. Gentile, G.A Chapman and W.A. Brungs. 1985; 822R85100. "Guidelines for Deriving National Water Quality Criteria for the Protection of Aquatic organisms and Their Uses". PB85–227049. National Technical Information Service Springfield, Va.
- 6. Barron, M.G., I.R. Schultz and W.L. Hayton. 1989. Presystemic brachial metabolism limits Di-2-Ethylhexyl Phthalate accumulation in fish. Toxicol. Appl. Pharmacol 98:48–57.

[FR Doc. 95-23844 Filed 9-25-95; 8:45 am] BILLING CODE 6560-50-P

FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission applications for licenses as ocean freight forwarders pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. app. 1718 and 46 CFR 510).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to contact the Office of Freight Forwarders, Federal Maritime Commission, Washington, DC 20573.

Presitge Forwarding Co., 13630 Destino Place, Cerritos, CA 90703, I Chen Chiang, Sole Proprietor

NACH 1 Air Services Incorporated, 615 South Madison Drive, Tempe, AZ 85281. Officers: Michael S. Entzminger, President, Charlotte Carpenter, Vice President

By the Federal Maritime Commission.

Dated: September 20, 1995.

Joseph C. Polking,

Secretary.

[FR Doc. 95-23743 Filed 9-25-95; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL TRADE COMMISSION

[Dkt. C-3593]

Nature's Bounty, Inc., et al.; Prohibited Trade Practices, and Affirmative Corrective Actions

AGENCY: Federal Trade Commission. **ACTION:** Consent order.

summary: In settlement of alleged violations of federal law prohibiting unfair acts and practices and unfair methods of competition, this consent order requires, among other things, the New York-based company and two of its wholly-owned subsidiaries to pay \$250,000 to the Commission for possible use for consumer redress, and requires them to have substantiation for specific health-related representations they make in advertising and promoting any product in the future.

DATES: Complaint and Order issued July 21, 1995.¹

FOR FURTHER INFORMATION CONTACT: Justin Dingfelder or Peter Metrinko, FTC/S-4631, Washington, DC 20580. (202) 326-3017 or 326-2104.

SUPPLEMENTARY INFORMATION: On Thursday, May 11, 1995, there was published in the Federal Register, 60 FR 25218, a proposed consent agreement with analysis In the Matter of Nature's Bounty, Inc., et al., for the purpose of soliciting public comment.

Interested parties were given sixty (60) days in which to submit comments, suggestions or objections regarding the proposed form of the order.

No comments having been received, the Commission has ordered the issuance of the complaint in the form contemplated by the agreement, made its jurisdictional findings and entered an order to cease and desist, as set forth in the proposed consent agreement, in disposition of this proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interprets or applies sec. 5, 38 Stat. 719, as amended; 15 U.S.C. 45, 52)

Donald S. Clark,

Secretary.

[FR Doc. 95–23795 Filed 9–25–95; 8:45 am] BILLING CODE 6750–01–M

[File No. 942-3161]

Genetus Alexandria, Inc., et al.; Proposed Consent Agreement With Analysis To Aid Public Comment

AGENCY: Federal Trade Commission. **ACTION:** Proposed consent agreement.

SUMMARY: In settlement of alleged violations of federal law prohibiting unfair acts and practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, would prohibit, among other things, a Virginia-based clinic and its operators from misrepresenting the nature or extent of a physician's participation in any treatment procedure, the safety or efficacy of any treatment procedure, and the extent to which a treatment is covered by a patient's medical insurance.

DATES: Comments must be received on or before November 27, 1995.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room 159, 6th St. and Pa. Ave., NW., Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Sondra Mills or Eric Bash, FTC/H–200, Washington, DC 20580. (202) 326–2673 or 326–2892.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act. 38 Stat. 721, 15 U.S.C. 46 and § 2.34 of the Commission's rules of practice (16 CFR 2.34), notice is hereby given that the following consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of sixty (60) days. Public comment is invited. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with § 4.9(b)(6)(ii) of the Commission's rules of practice (16 CFR 4.9(b)(6)(ii)).

In the matter of Genetus Alexandria, Inc., a corporation, and Galen Medical Centers, Ltd., a corporation, and George Oprean, individually and as President and a director of Genetus Alexandria, Inc. and Galen Medical Centers, Ltd., and Linda Huffman Oprean, individually and as an officer and a director of Genetus Alexandria, Inc. and as a director of Galen Medical Centers, Ltd.

Agreement Containing Consent Order To Cease and Desist

The Federal Trade Commission having initiated an investigation of certain acts and practices of Genetus Alexandria, Inc., a corporation ("Genetus"), Galen Medical Centers,

¹Copies of the Complaint, the Decision and Order, and Commissioner Azcuenaga's statement are available from the Commission's Public Reference Branch, H–130, 6th Street & Pennsylvania Avenue, NW., Washington, DC 20580.